Glaukos (GKOS)

• Market cap: $5.38B
• 1 day: 0.45%
• 5 days: 0.49%
• 1 month: -4.24%
• 3 months: -40.25%
• 6 months: -32.04%
• Year to date: -37.03%
• 1 year: -1.82%
• 5 years: 156.88%
• 10 years: 201.89%
• Sector: Healthcare
• Industry: Medical Devices

About: Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Employees: 995

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

33% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 40

21% more capital invested

Capital invested by funds: $7.08B [Q3] → $8.57B (+$1.49B) [Q4]

5.52% more ownership

Funds ownership: 107.89% [Q3] → 113.41% (+5.52%) [Q4]

2% more funds holding

Funds holding: 312 [Q3] → 318 (+6) [Q4]

10% more repeat investments, than reductions

Existing positions increased: 115 | Existing positions reduced: 105

0% more funds holding in top 10

Funds holding in top 10: 6 [Q3] → 6 (+0) [Q4]

29% less call options, than puts

Call options by funds: $46.1M | Put options by funds: $64.7M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $140 49% upside
• Avg. target: $163 73% upside
• High target: $176 87% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

Mizuho Anthony Petrone 45% 1-year accuracy 10 / 22 met price target	86% upside $175	Outperform Maintained	16 Apr 2025
Piper Sandler Matt O'Brien 46% 1-year accuracy 23 / 50 met price target	75% upside $165	Overweight Maintained	15 Apr 2025
Truist Securities Richard Newitter 57% 1-year accuracy 29 / 51 met price target	49% upside $140	Buy Maintained	11 Apr 2025
Wells Fargo Larry Biegelsen 27% 1-year accuracy 12 / 44 met price target	70% upside $160	Overweight Maintained	21 Feb 2025
Needham David Saxon 40% 1-year accuracy 26 / 65 met price target	87% upside $176	Buy Maintained	21 Feb 2025